相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Certolizumab pegol for the treatment of rheumatoid arthritis
Sarah Horton et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
A new site-specific monoPEGylated filgrastim derivative prepared by enzymatic conjugation: Production and physicochemical characterization
Silvia Scaramuzza et al.
JOURNAL OF CONTROLLED RELEASE (2012)
State of the art in PEGylation: The great versatility achieved after forty years of research
Gianfranco Pasut et al.
JOURNAL OF CONTROLLED RELEASE (2012)
Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: results from the REALISTIC phase IIIb study
Michael E. Weinblatt et al.
RHEUMATOLOGY (2012)
Predicting Future Response to Certolizumab Pegol in Rheumatoid Arthritis Patients: Features at 12 Weeks Associated With Low Disease Activity at 1 Year
Jeffrey R. Curtis et al.
ARTHRITIS CARE & RESEARCH (2012)
Pegloticase In Treatment-Refractory Chronic Gout
Katherine A. Lyseng-Williamson
DRUGS (2011)
Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Biologic Agents in Rheumatoid Arthritis: An Update for Managed Care Professionals
Sandeep K. Agarwal
JOURNAL OF MANAGED CARE PHARMACY (2011)
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial
J. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
R. Fleischmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Emerging PEGylated drugs
Jung Seok Kang et al.
EXPERT OPINION ON EMERGING DRUGS (2009)
Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout - Results of a phase II randomized study
John S. Sundy et al.
ARTHRITIS AND RHEUMATISM (2008)
Certolizumab Pegol Plus Methotrexate Is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis Findings of a Fifty-Two-Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
Edward Keystone et al.
ARTHRITIS AND RHEUMATISM (2008)
Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients
Jonathan K. Armstrong et al.
CANCER (2007)
Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout
John S. Sundy et al.
ARTHRITIS AND RHEUMATISM (2007)
Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase
NJ Ganson et al.
ARTHRITIS RESEARCH & THERAPY (2006)
Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases
CK Edwards et al.
ADVANCED DRUG DELIVERY REVIEWS (2003)
Interactions between PEG and type I soluble tumor necrosis factor receptor: Modulation by pH and by PEGylation at the N terminus
BA Kerwin et al.
PROTEIN SCIENCE (2002)
Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis
A Coxon et al.
ARTHRITIS AND RHEUMATISM (2002)
Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial
EHS Choy et al.
RHEUMATOLOGY (2002)
Structure, biology, and therapeutic implications of pegylated interferon alpha-2b
S Youngster et al.
CURRENT PHARMACEUTICAL DESIGN (2002)
Structural and biologic characterization of pegylated recombinant IFN-α2b
M Grace et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2001)
分享论文
